The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for ...

Company prepares to advance to Phase 2 clinical trial in early 2025 HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- (March Bio), an emerging clinical stage biotechnology company committed to combating ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

Revlimid is a medicine used to treat certain cancers and serious conditions affecting blood cells and bone marrow.

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

A Shuswap woman who has endeavoured to support fellow survivors of child sexual abuse is now the focus of community giving.

Recent years have witnessed notable progress in tailoring treatments for solid tumors using biomarkers. Nevertheless, identifying specific biomarkers for ...